Highlights Belite Bio, Inc

Equities

BLTE

US07782B1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
48.55 ^USD	-0.92%		-1.32%	+6.12%

Jun. 12	Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan	MT
Jun. 12	Belite Bio, Inc. Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan	Jun. 12	MT
Belite Bio, Inc. Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan	Jun. 12	CI
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Belite Bio's Q1 Loss Narrows	May. 14	MT
Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting	May. 06	CI
Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	Mar. 22	CI
ADRs End Higher, ATRenew Inc. Climbs 26.9%	Mar. 12	DJ
Belite Bio's Q4 Loss Narrows	Mar. 12	MT
Belite Bio, Inc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Belite Bio, Inc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Belite Bio Gets Clearance to Launch Tinlarebant Phase 3 Trial for Eye Disease in China	Dec. 27	MT
Belite Bio, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Belite Bio's Q3 Loss Widens	Nov. 14	MT
Belite Bio, Inc. Presents Results from a 24-Month, Phase 2 Study of Tinlarebant in Childhood-Onset Stargardt Disease at the AAO Annual Meeting	Nov. 06	CI
Belite Bio, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Belite Bio, Inc. Doses First Subject in Pivotal Phase 3 Phoenix Trial Evaluating Oral Tinlarebant for Ga	23-07-27	CI
Belite Bio, Inc. Completes Enrollment in Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant for Stargardt Disease	23-07-24	CI
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Belite Bio Finalizes Study Design for Late-Stage Trial of Tinlarebant to Treat Geographic Atrophy Associated with Dry AMD	22-11-18	MT
Belite Bio, Inc Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)	22-11-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Belite Bio, Inc

Equities

BLTE

US07782B1044

Highlights

Filters